Literature DB >> 22726567

Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia?

M J Gandal1, R L Anderson, E N Billingslea, G C Carlson, T P L Roberts, S J Siegel.   

Abstract

Reduced NMDA-receptor (NMDAR) function has been implicated in the pathophysiology of neuropsychiatric disease, most strongly in schizophrenia but also recently in autism spectrum disorders (ASD). To determine the direct contribution of NMDAR dysfunction to disease phenotypes, a mouse model with constitutively reduced expression of the obligatory NR1 subunit has been developed and extensively investigated. Adult NR1(neo-/-) mice show multiple abnormal behaviors, including reduced social interactions, locomotor hyperactivity, self-injury, deficits in prepulse inhibition (PPI) and sensory hypersensitivity, among others. Whereas such phenotypes have largely been interpreted in the context of schizophrenia, these behavioral abnormalities are rather non-specific and are frequently present across models of diseases characterized by negative symptom domains. This study investigated auditory electrophysiological and behavioral paradigms relevant to autism, to determine whether NMDAR hypofunction may be more consistent with adult ASD-like phenotypes. Indeed, transgenic mice showed behavioral deficits relevant to all core ASD symptoms, including decreased social interactions, altered ultrasonic vocalizations and increased repetitive behaviors. NMDAR disruption recapitulated clinical endophenotypes including reduced PPI, auditory-evoked response N1 latency delay and reduced gamma synchrony. Auditory electrophysiological abnormalities more closely resembled those seen in clinical studies of autism than schizophrenia. These results suggest that NMDAR hypofunction may be associated with a continuum of neuropsychiatric diseases, including schizophrenia and autism. Neural synchrony abnormalities suggest an imbalance of glutamatergic and GABAergic coupling and may provide a target, along with behavioral phenotypes, for preclinical screening of novel therapeutics.
© 2012 The Authors. Genes, Brain and Behavior © 2012 Blackwell Publishing Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22726567      PMCID: PMC3808979          DOI: 10.1111/j.1601-183X.2012.00816.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  95 in total

Review 1.  Mouse behavioral endophenotypes for schizophrenia.

Authors:  Laura C Amann; Michael J Gandal; Tobias B Halene; Richard S Ehrlichman; Samantha L White; Hilary S McCarren; Steven J Siegel
Journal:  Brain Res Bull       Date:  2010-04-28       Impact factor: 4.077

2.  Validating γ oscillations and delayed auditory responses as translational biomarkers of autism.

Authors:  Michael J Gandal; J Christopher Edgar; Richard S Ehrlichman; Mili Mehta; Timothy P L Roberts; Steven J Siegel
Journal:  Biol Psychiatry       Date:  2010-12-15       Impact factor: 13.382

Review 3.  Behavioural phenotyping assays for mouse models of autism.

Authors:  Jill L Silverman; Mu Yang; Catherine Lord; Jacqueline N Crawley
Journal:  Nat Rev Neurosci       Date:  2010-07       Impact factor: 34.870

4.  Mice with reduced NMDA receptor expression display behaviors related to schizophrenia.

Authors:  A R Mohn; R R Gainetdinov; M G Caron; B H Koller
Journal:  Cell       Date:  1999-08-20       Impact factor: 41.582

5.  40- and 70-kHz vocalizations of mice (Mus musculus) during copulation.

Authors:  N R White; M Prasad; R J Barfield; J G Nyby
Journal:  Physiol Behav       Date:  1998-02-15

Review 6.  The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.

Authors:  J D Jentsch; R H Roth
Journal:  Neuropsychopharmacology       Date:  1999-03       Impact factor: 7.853

Review 7.  Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy.

Authors:  M L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  1998       Impact factor: 3.575

8.  Brief report: Sensorimotor gating in idiopathic autism and autism associated with fragile X syndrome.

Authors:  Jennifer Yuhas; Lisa Cordeiro; Flora Tassone; Elizabeth Ballinger; Andrea Schneider; James M Long; Edward M Ornitz; David Hessl
Journal:  J Autism Dev Disord       Date:  2011-02

9.  Autistic disorders and schizophrenia: related or remote? An anatomical likelihood estimation.

Authors:  Charlton Cheung; Kevin Yu; Germaine Fung; Meikei Leung; Clive Wong; Qi Li; Pak Sham; Siew Chua; Gráinne McAlonan
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

10.  Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes.

Authors:  Hsiao-Tuan Chao; Hongmei Chen; Rodney C Samaco; Mingshan Xue; Maria Chahrour; Jong Yoo; Jeffrey L Neul; Shiaoching Gong; Hui-Chen Lu; Nathaniel Heintz; Marc Ekker; John L R Rubenstein; Jeffrey L Noebels; Christian Rosenmund; Huda Y Zoghbi
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

View more
  51 in total

Review 1.  Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse.

Authors:  Joseph T Coyle; W Brad Ruzicka; Darrick T Balu
Journal:  Am J Psychiatry       Date:  2020-12-01       Impact factor: 18.112

2.  A Predictive Coding Account of Psychotic Symptoms in Autism Spectrum Disorder.

Authors:  Gerrit I van Schalkwyk; Fred R Volkmar; Philip R Corlett
Journal:  J Autism Dev Disord       Date:  2017-05

Review 3.  Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models.

Authors:  D Sinclair; B Oranje; K A Razak; S J Siegel; S Schmid
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

4.  Severity of ASD symptoms and their correlation with the presence of copy number variations and exposure to first trimester ultrasound.

Authors:  Sara Jane Webb; Michelle M Garrison; Raphael Bernier; Abbi M McClintic; Bryan H King; Pierre D Mourad
Journal:  Autism Res       Date:  2016-09-01       Impact factor: 5.216

5.  Parvalbumin Cell Ablation of NMDA-R1 Leads to Altered Phase, But Not Amplitude, of Gamma-Band Cross-Frequency Coupling.

Authors:  Russell G Port; Jeffrey I Berman; Song Liu; Robert E Featherstone; Timothy P L Roberts; Steven J Siegel
Journal:  Brain Connect       Date:  2019-03-15

6.  Tonic Activation of GluN2C/GluN2D-Containing NMDA Receptors by Ambient Glutamate Facilitates Cortical Interneuron Maturation.

Authors:  Elizabeth Hanson; Moritz Armbruster; Lauren A Lau; Mary E Sommer; Zin-Juan Klaft; Sharon A Swanger; Stephen F Traynelis; Stephen J Moss; Farzad Noubary; Jayashree Chadchankar; Chris G Dulla
Journal:  J Neurosci       Date:  2019-03-07       Impact factor: 6.167

7.  Repetitive behavior profile and supersensitivity to amphetamine in the C58/J mouse model of autism.

Authors:  Sheryl S Moy; Natallia V Riddick; Viktoriya D Nikolova; Brian L Teng; Kara L Agster; Randal J Nonneman; Nancy B Young; Lorinda K Baker; Jessica J Nadler; James W Bodfish
Journal:  Behav Brain Res       Date:  2013-11-08       Impact factor: 3.332

8.  Exploring the relationship between cortical GABA concentrations, auditory gamma-band responses and development in ASD: Evidence for an altered maturational trajectory in ASD.

Authors:  Russell G Port; William Gaetz; Luke Bloy; Dah-Jyuu Wang; Lisa Blaskey; Emily S Kuschner; Susan E Levy; Edward S Brodkin; Timothy P L Roberts
Journal:  Autism Res       Date:  2016-10-01       Impact factor: 5.216

Review 9.  Cellular and circuit models of increased resting-state network gamma activity in schizophrenia.

Authors:  R S White; S J Siegel
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

10.  Reversal of social deficits by subchronic oxytocin in two autism mouse models.

Authors:  Brian L Teng; Viktoriya D Nikolova; Natallia V Riddick; Kara L Agster; James J Crowley; Lorinda K Baker; Beverly H Koller; Cort A Pedersen; Michael B Jarstfer; Sheryl S Moy
Journal:  Neuropharmacology       Date:  2015-12-31       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.